Clinical Trials › NCT04688788
Active, Not RecruitingPhase 3
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
Sponsored by Rigshospitalet, Denmark
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 600
Target enrollment
Apr 2021
Start date
May 2029
Expected completion
Interventions / Treatments
RituximabOcrelizumabFexofenadineParacetamolMethylprednisolone
Conditions studied
Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.